Catalyst
Slingshot members are tracking this event:
GW Pharma (GWPH) to File New Drug Application (NDA) for Epidiolex in Dravet Syndrome and Lennox-Gastaut-Syndrome (LGS) in H1 of 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| GWPH |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 07, 2017
Occurred Source:
http://ir.gwpharm.com/releasedetail.cfm?ReleaseID=1036344
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Epidiolex, Dravet Syndrome, Lennox-gastaut Syndrome, Fda, Nda, New Drug Application
